


SARS-CoV-2

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase)


Catalog # DE0007 Size 1 Kit

Applications



Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells



Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).

Specification	
Product Description	COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly sen sitive and quantitative measurement of neutralizing antibodies.
Supplied Product	Kit content: 1 kit is sufficient for 100 assays in 24 well plates 1. 293T-hACE2 cell, 2x10 ⁶ cells/vial, FBS with 10% DMSO 2. SARS-CoV-2 Delta Variant Pseudovirus Expressing Luciferase



Product Information

Materials Required But NOT Supplied	 SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova ZymeFree™ Enzyme Free Cell Dissociation Reagent, Cat# TCL028-100ML, HIMEDIA DMEM culture medium containing 10% FBS (complete medium) Luciferase Assay System, Cat# E1500, Promega a. Luciferase Assay Substrate (lyophilized) b. Luciferase Assay Buffer c. Luciferase Cell Culture Lysis Reagent, 5X TC-Treated 24 Well Plates, Cat# 3524, Corning OptiPlate™-96, Cat# 6005290, PerkinElmer
Variant	B.1.617.2
Suitable Sample	 Immunized Serum Infected Serum Neutralizing Antibodies Peptide Inhibitors or Proteins Compounds Targeting Spike Induced Cell Fusion
Sample Volume	10-50 uL (please check sample source)
Detection Method	Luciferase Activity
Technology	<u>Pseudovirus</u>
Regulatory Status	For research use only (RUO)
Storage Instruction	293T-hACE2 cell Store at liquid nitrogen. Pseudovirus Store at -80°C. Aliquot to avoid repeated freezing and thawing.

Applications

Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells.

Neutralization

RBD-binding lgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).